ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1419

Effectivenss of an educational program on non-radiographic axial spondyloarthritis
Abstract Number: 0273

Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis
Abstract Number: 2552

Effects of 360° Virtual Reality Embodiment Videos on Pain in Hand Osteoarthritis: A Within-Subject Pre-Post Study
Abstract Number: 0973

Effects of a Novel Hybrid Protein Based on S100 on Macrophage Polarization and Its Therapeutic Efficacy in a Bleomycin-Induced Systemic Sclerosis Mouse Model.
Abstract Number: 0581

Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Abstract Number: 0712

Effects of Bacterial Secretome on Nasal Epithelial Cell Gene Expression in ANCA-Associated Vasculitis
Abstract Number: 0660

Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
Abstract Number: 0878

Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study
Abstract Number: 0393

Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis
Abstract Number: 0573

Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Abstract Number: 2289

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study
Abstract Number: 0766

Effects of Walking During the 6-Minute Walk Test on Cognition in Adults with Knee Replacement
Abstract Number: 0662

Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
Abstract Number: 1134

Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
Abstract Number: 1518

Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].